Biotech
Crystalys Therapeutics
Crystalys Therapeutics raises $205M Series B at $900M valuation
$205M
Total Raised
Series B
Latest Round
2021
Founded
110+
Employees
Boston, MA
1 min read
Quick Facts
Valuation
$900M
Latest Round Size
$205M
Latest Round Date
October 2025
Crystalys Therapeutics: Series B Funding Round
Crystalys Therapeutics has successfully raised $205M in Series B funding, reaching a valuation of $900M.
Company Overview
Developing novel therapeutics for neurodegenerative diseases
Funding Details
The Series B round was led by Fidelity, with participation from Viking Global.
Company Information
- Headquarters: Boston, MA
- Founded: 2021
- Employees: 110+
- Category: Biotech
Investment
Crystalys Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series B
- Viking Global: Verified investor in Series B
Key Investors
Fidelity
Lead Investor
Verified investor in Series B
Viking Global
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M